Spots Global Cancer Trial Database for Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
Official Title: Clinical Application Study of Transarterial Chemoembolization Containing Arsenic Trioxide in the Treatment of Hepatocellular Carcinoma
Study ID: NCT02018757
Conditions
Study Description
Brief Summary: The purpose of the study is to determine whether transarterial chemoembolization containing arsenic trioxide is safe and effective in the treatment of intermediate-stage hepatocellular carcinoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
Xijing Hospital，Fourth Military Medical University, Xi'an, Shaanxi, China
Zhongshan Hospital Fudan University, Shanghai, , China
Contact Details
Name: Haibo Shao, MD,PhD
Affiliation: First Hospital of China Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
